Page last updated: 2024-12-11
n-palmitoylgalactosylsphingosine
Description
N-(hexadecanoyl)-beta-D-galactosylsphingosine : A D-galactosyl-N-acylsphingosine in which the ceramide N-acyl group is specified as hexadecanoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (19)
Synonym |
n-palmitoylgalactosylsphingosine |
34324-89-5 |
n-palmitoylpsychosine |
CHEBI:83259 |
n-(hexadecanoyl)-1-beta-galactosyl-sphing-4-enine |
beta-d-galactosyl-n-hexadecanoylsphingosine |
n-(palmitoyl)-beta-d-galactosylsphingosine |
n-hexadecanoyl-beta-d-galactosyl-sphing-4-enine |
n-(hexadecanoyl)-beta-d-galactosylsphingosine |
n-[(2s,3r,4e)-1-(beta-d-galactopyranosyloxy)-3-hydroxyoctadec-4-en-2-yl]hexadecanamide |
beta-d-galactosyl-n-palmitoylsphingosine |
n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]hexadecanamide |
hexadecanamide, n-[(1s,2r,3e)-1-[(beta-d-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]- |
n-palmitoyl cerebroside |
Q27105092 |
hexadecanamide,n-[(1s,2r,3e)-1-[(beta-d-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]- |
DTXSID901120367 |
n-[(1s,2r,3e)-1-[(beta-d-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]hexadecanamide |
c16 galactosylceramide (d18:1/16:0) |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
"After 6 months, the EYEMATE-SC sensor was safe and well tolerated, and allowed continual IOP monitoring." | ( Safety and performance of a suprachoroidal sensor for telemetric measurement of intraocular pressure in the EYEMATE-SC trial. Dick, HB; Hoffmann, EM; Mackert, M; Mansouri, K; Mermoud, A; Rao, HL; Seuthe, AM; Szurman, P; Weinreb, RN, 2023) | 0.91 |
"Device position and adverse events." | ( EYEMATE-SC Trial: Twelve-Month Safety, Performance, and Accuracy of a Suprachoroidal Sensor for Telemetric Measurement of Intraocular Pressure. Dick, HB; Gillmann, K; Hoffmann, EM; Mackert, MJ; Mansouri, K; Mermoud, A; Rao, HL; Seuthe, AM; Szurman, P; Weinreb, RN, 2023) | 0.91 |
"The EYEMATE-SC sensor was safe and well tolerated through 12 months." | ( EYEMATE-SC Trial: Twelve-Month Safety, Performance, and Accuracy of a Suprachoroidal Sensor for Telemetric Measurement of Intraocular Pressure. Dick, HB; Gillmann, K; Hoffmann, EM; Mackert, MJ; Mansouri, K; Mermoud, A; Rao, HL; Seuthe, AM; Szurman, P; Weinreb, RN, 2023) | 0.91 |
Roles (1)
Role | Description |
mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
N-acyl-beta-D-galactosylsphingosine | An N-acyl-D-galactosylsphingosine in which the anomeric configuration of the galactosyl residue is beta; sphingosine substituted at the O-1 position by a beta-D-galactosyl group and at the N-2 position by an acyl group. |
HexCer(d18:1/16:0) | A cerebroside in which the ceramide N-acyl group is specified as hexadecanoyl. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (13)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 6 (46.15) | 18.7374 |
1990's | 3 (23.08) | 18.2507 |
2000's | 1 (7.69) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (23.08) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 1 (7.69%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (92.31%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |